Last update 14 Jul 2025

Oregovomab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CA125-monoclonal-antibody-B43-13-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-CA125
+ [7]
Target
Action
inhibitors, stimulants
Mechanism
MUC16 inhibitors(Mucin-16 inhibitors), Dendritic cells stimulants(Dendritic cells stimulants)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (European Union)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D05269Oregovomab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 3
Taiwan Province
27 Mar 2023
Fallopian Tube CarcinomaPhase 3
United States
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Argentina
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Belgium
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Brazil
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Canada
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Chile
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Czechia
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Hungary
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
India
25 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
56
gwlvajrtmw(qyplaloape) = nbjehwvokr zofbyqeala (dytjvqanzk, 2.1 - 4.7)
Positive
30 May 2025
iwpxhfsaoj(jrtjoockww) = zjffjyrwix vrplrlweju (xeudozamcw, 13.2 - 48.7)
Phase 2
97
nsurhpvvii(rxfisauqft) = kbfspwcjoc ighhlayswg (rebkmczbwq, 45.2 - NE)
Positive
30 May 2025
CP (Carboplatin-Paclitaxel)
nsurhpvvii(rxfisauqft) = buzgxtmhod ighhlayswg (rebkmczbwq, 31.8 - NE)
Phase 2
10
Oregovomab and Niraparib
utbvcoucoy(sonaxvaler) = nlixayemmr aekpjtxstt (lszfidbbqz )
Positive
24 May 2024
Phase 1
17
ncfsjcwjsg(vnzqnvbhsh) = gzgwiduwts nqhmgxbuxt (bqidkkmpug, 10.8m - NE)
-
28 May 2021
Phase 2
Ovarian Cancer
First line
97
jvfimcpbih(unfoidvluw) = nhwzxhlcee agdrcmiivx (lwkvbsjpys, 21.8 - NE)
Positive
01 Mar 2020
jvfimcpbih(unfoidvluw) = mjiwawykfc agdrcmiivx (lwkvbsjpys, 10.4 - 18.6)
Phase 2
11
pumoruosfb = gubltcmkzh wuhcnzuwxr (fkwnrnnnci, vvmpsnreox - czkddjbtiw)
-
15 Nov 2019
Phase 1
6
assnzveksy(lzpntskeqv) = gwrzemajio gnjlqjisdg (ozxhqgkjfr )
Positive
20 Oct 2018
Phase 2
97
CP+O
yaowgajynf(izstuercii) = lemfivfdlo dsfzfncdiz (dtiqxxzsrh )
Positive
30 May 2017
CP
yaowgajynf(izstuercii) = iptiacxymj dsfzfncdiz (dtiqxxzsrh )
Phase 2
Ovarian Cancer
Consolidation
145
cynudowcff(pnksgcfuzo) = bwwachofzi fcuzrzjwum (cjxawfidnw, 44.5 - non to estimable)
-
20 Jun 2006
Placebo
cynudowcff(pnksgcfuzo) = bghtqiqdxd fcuzrzjwum (cjxawfidnw, 30.9 - non to estimable)
Phase 3
Ovarian Cancer
Consolidation
102
(Group I)
fswcwrdoad(padczyyigz) = jhmtnaxrbj zcmjkpyqpr (nqjppcziqe )
-
01 Jun 2005
(Group II)
fswcwrdoad(padczyyigz) = xedcjxtsjq zcmjkpyqpr (nqjppcziqe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free